Innate Pharma SA (FR:IPH) has released an update.
Innate Pharma has announced a strategic leadership change with Jonathan Dickinson as the new CEO, along with promising FDA feedback for its lacutamab development and IND approval for IPH4502 aimed at treating solid tumors. The company is set to present significant data at upcoming medical conferences, reflecting its strong research momentum. With a healthy cash position of €96.4 million, Innate Pharma is well-poised for continued growth and innovation in cancer treatment.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
